226330 — Syntekabio Share Price
Last trade - 00:00- KR₩108bn
- KR₩96bn
- KR₩123m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.64 | ||
| Price to Tang. Book | 3.69 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 885.76 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -39.5% | ||
| Return on Equity | -31.62% | ||
| Operating Margin | -10337.22% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 461.37 | 609.68 | 316.66 | 243.99 | 123.41 | n/a | n/a | -15.51% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Syntekabio,Inc. is a Korea-based company principally engaged in the provision of database and software. The Company develops and sells software such as personal algorithm dielectric map platform (PMAP) using artificial intelligence (AI) technology, provides clinical trial modeling and genome analysis services through big data. The analysis results are used to diagnose genetic diseases, select biomarker treatments and predict disease risk. In addition, the Company develops AI drug development technology, provides research services for candidate substances of immuno-cancer drugs.
Directors
- Jong Seon Jung CCE (57)
- Tae Sun Kim CCE (45)
- Ok Gu Kang CFO (42)
- Seok Jun Lee OTH (62)
- Hyeon Jin Yang OTH (41)
- Jong Hui Hong DRC (46)
- Hyeong Rae Kim NID (65)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- September 15th, 2009
- Public Since
- December 17th, 2019
- No. of Shareholders
- 27,104
- No. of Employees
- 48
- Sector
- Software & IT Services
- Industry
- Technology
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 15,258,475
- Address
- 1903, Expo Tower, 1, Expo-ro, Yuseong-gu, DAEJEON, 34126
- Web
- https://www.syntekabio.com/
- Phone
- +82 29600982
- Auditors
- KPMG Samjong Accounting Corp
Upcoming Events for 226330
Similar to 226330
Action Square Co
Korea Exchange - KOSDAQ
Actoz Soft Co
Korea Exchange - KOSDAQ
Ahnlab
Korea Exchange - KOSDAQ
Alchera
Korea Exchange - KOSDAQ
Alticast
Korea Exchange - KOSDAQ
FAQ
As of Today at 23:36 UTC, shares in Syntekabio are trading at KR₩7,340. This share price information is delayed by 15 minutes.
Shares in Syntekabio last closed at KR₩7,340 and the price had moved by -33.45% over the past 365 days. In terms of relative price strength the Syntekabio share price has underperformed the FTSE Developed Asia Pacific Index by -36.32% over the past year.
There is no consensus recommendation for this security.
Syntekabio does not currently pay a dividend.
Syntekabio does not currently pay a dividend.
Syntekabio does not currently pay a dividend.
To buy shares in Syntekabio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩7,340, shares in Syntekabio had a market capitalisation of KR₩112bn.
Here are the trading details for Syntekabio:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 226330
Based on an overall assessment of its quality, value and momentum Syntekabio is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Syntekabio. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -47.71%.
As of the last closing price of KR₩7,340, shares in Syntekabio were trading -36.97% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Syntekabio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩7,340.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Syntekabio's management team is headed by:
- Jong Seon Jung - CCE
- Tae Sun Kim - CCE
- Ok Gu Kang - CFO
- Seok Jun Lee - OTH
- Hyeon Jin Yang - OTH
- Jong Hui Hong - DRC
- Hyeong Rae Kim - NID